These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 33705876)

  • 41. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
    Yu J; Chan HK; Gengenbach T; Denman JA
    Eur J Pharm Biopharm; 2017 Oct; 119():224-234. PubMed ID: 28655664
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Development of Inhalable Dry Powder Formulations Loaded with Nanoparticles Maintaining Their Original Physical Properties and Functions].
    Okuda T
    Yakugaku Zasshi; 2017; 137(11):1339-1348. PubMed ID: 29093369
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
    Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
    Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Formulation techniques for high dose dry powders.
    Brunaugh AD; Smyth HDC
    Int J Pharm; 2018 Aug; 547(1-2):489-498. PubMed ID: 29778822
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pulmonary drug delivery by powder aerosols.
    Yang MY; Chan JG; Chan HK
    J Control Release; 2014 Nov; 193():228-40. PubMed ID: 24818765
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying.
    Saboti D; Maver U; Chan HK; Planinšek O
    J Pharm Sci; 2017 Jul; 106(7):1881-1888. PubMed ID: 28285981
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The dispersion behaviour of dry powder inhalation formulations cannot be assessed at a single inhalation flow rate.
    Grasmeijer F; de Boer AH
    Int J Pharm; 2014 Apr; 465(1-2):165-8. PubMed ID: 24548720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro and in vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization.
    Wang YB; Watts AB; Peters JI; Liu S; Batra A; Williams RO
    AAPS PharmSciTech; 2014 Aug; 15(4):981-93. PubMed ID: 24824172
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Particle engineering in dry powders for inhalation.
    Scherließ R; Bock S; Bungert N; Neustock A; Valentin L
    Eur J Pharm Sci; 2022 May; 172():106158. PubMed ID: 35248734
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
    Minne A; Boireau H; Horta MJ; Vanbever R
    Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis.
    Young PM; Salama RO; Zhu B; Phillips G; Crapper J; Chan HK; Traini D
    Drug Dev Ind Pharm; 2015 May; 41(5):859-65. PubMed ID: 24811055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of an Excipient-Free Peptide Dry Powder Inhalation for the Treatment of Pulmonary Fibrosis.
    Zhang Y; MacKenzie B; Koleng JJ; Maier E; Warnken ZN; Williams RO
    Mol Pharm; 2020 Feb; 17(2):632-644. PubMed ID: 31913640
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria.
    Wang J; Kutter JP; Mu H; Moodley A; Yang M
    Int J Pharm; 2020 Nov; 590():119877. PubMed ID: 32927003
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies.
    Meenach SA; Anderson KW; Hilt JZ; McGarry RC; Mansour HM
    AAPS PharmSciTech; 2014 Dec; 15(6):1574-87. PubMed ID: 25139763
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.
    Lin YW; Wong J; Qu L; Chan HK; Zhou QT
    Curr Pharm Des; 2015; 21(27):3902-16. PubMed ID: 26290193
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance.
    Bosquillon C; Lombry C; Préat V; Vanbever R
    J Control Release; 2001 Feb; 70(3):329-39. PubMed ID: 11182203
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach.
    Karimi K; Pallagi E; Szabó-Révész P; Csóka I; Ambrus R
    Drug Des Devel Ther; 2016; 10():3331-3343. PubMed ID: 27784991
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhalable dry powder formulations of siRNA and pH-responsive peptides with antiviral activity against H1N1 influenza virus.
    Liang W; Chow MY; Lau PN; Zhou QT; Kwok PC; Leung GP; Mason AJ; Chan HK; Poon LL; Lam JK
    Mol Pharm; 2015 Mar; 12(3):910-21. PubMed ID: 25599953
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
    Muralidharan P; Hayes D; Mansour HM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Co-Spray-Dried Urea Cross-Linked Hyaluronic Acid and Sodium Ascorbyl Phosphate as Novel Inhalable Dry Powder Formulation.
    Fallacara A; Busato L; Pozzoli M; Ghadiri M; Ong HX; Young PM; Manfredini S; Traini D
    J Pharm Sci; 2019 Sep; 108(9):2964-2971. PubMed ID: 31009614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.